Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $18.7 million.

  • BioXcel Therapeutics' Net Cash Flow rose 21801.18% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year increase of 9381.33%. This contributed to the annual value of -$35.4 million for FY2024, which is 7247.79% up from last year.
  • Per BioXcel Therapeutics' latest filing, its Net Cash Flow stood at $18.7 million for Q3 2025, which was up 21801.18% from -$12.4 million recorded in Q2 2025.
  • BioXcel Therapeutics' Net Cash Flow's 5-year high stood at $18.7 million during Q3 2025, with a 5-year trough of -$38.6 million in Q4 2022.
  • In the last 4 years, BioXcel Therapeutics' Net Cash Flow had a median value of -$17.9 million in 2024 and averaged -$17.5 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 320263.62% in 2023, then skyrocketed by 21801.18% in 2025.
  • Over the past 4 years, BioXcel Therapeutics' Net Cash Flow (Quarter) stood at -$38.6 million in 2022, then surged by 35.89% to -$24.7 million in 2023, then soared by 57.43% to -$10.5 million in 2024, then skyrocketed by 277.96% to $18.7 million in 2025.
  • Its Net Cash Flow was $18.7 million in Q3 2025, compared to -$12.4 million in Q2 2025 and $1.2 million in Q1 2025.